Last reviewed · How we verify
AN2025
At a glance
| Generic name | AN2025 |
|---|---|
| Also known as | BKM120 |
| Sponsor | Adlai Nortye Biopharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (PHASE3)
- Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AN2025 CI brief — competitive landscape report
- AN2025 updates RSS · CI watch RSS
- Adlai Nortye Biopharma Co., Ltd. portfolio CI